吉非替尼联合放射治疗对非小细胞肺癌脑转移的临床效果分析

Analysis of the clinical Effect of Gefitinib combined with Radiotherapy on Brain Metastases from non-small-cell Lung Carcinoma

目的吉非替尼联合放射治疗对非小细胞肺癌脑转移的临床效果分析。方法选取2018年1月—2019年1月收治于河南省商丘市第一人民医院的60例非小细胞肺癌脑转移患者,按照患者入院顺序单双号随机将60例患者分为实验组和对照组,每组各30例,实验组患者使用吉非替尼联合放射进行治疗,对照组进行单独放疗,对比两组患者临床效果。结果实验组患者有效率RR为76.67%、疾病控制率DCR为96.67%;对照组患者有效率RR为36.67%、疾病控制率DCR为70.00%,组间比较实验组数据明显优于对照组,数据差异显著(P<0.05),具有统计学意义。结论吉非替尼联合放射治疗对非小细胞肺癌脑转移临床效果显著,在近期疗效以及疾病控制上效果更佳。

Objective To analyze the clinical effect of gefitinib combined with radiotherapy on non-small-cell lung carcinoma brain metastasis.Methods A total of 60 patients with non-small-cell lung carcinoma brain metastases admitted to the First People's Hospital of Shangqiu city,Henan province from January 2018 to January 2019 were randomly divided into experimental group and control group according to the order of admission,there were 30 patients in each group.The patients in the experimental group were treated with gefitinib combined with radiotherapy.The patients in the control group were treated with radiotherapy alone,the clinical effects of the two groups were compared.Results the effective rate of the experimental group was 76.67%and the disease control rate of DCR was 96.67%,while the effective rate of the control group was 36.67%and the disease control rate of DCR was 70.00%,the data difference was significant(P<0.05).Conclusion Gefitinib combined with radiotherapy is effective in the treatment of non-small-cell lung carcinoma brain metastases,especially in the short term and in the control of the disease.